JPRN-jRCT2080222170未知2 期
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemia
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 80age old（—）
- 性别
- All
入选标准
- •Patients (over 20 years of age and under 80 years of age) with Hypercholesterolemia
- •Patient who is on a stable diet and on a stable daily dose of statin
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolEUCTR2013-000622-55-DKEli Lilly and Company528
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolEUCTR2013-000622-55-NLEli Lilly and Company528
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolPrimary hypercholesterolaemiaMedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000622-55-CZEli Lilly and Company528
已完成
2 期
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients with Primary Hypercholesterolemiahypercholesterolaemiahigh blood cholesterol levelsNL-OMON38601Eli Lilly80
进行中（未招募）
不适用
A study comparing several dose levels of LY3015014 in patients with high cholesterol studying the safety and ability of LY3015014 to reduce cholesterolPrimary hypercholesterolaemiaMedDRA version: 14.1Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000622-55-PLEli Lilly and Company528